Login
$EDIT
$1.96 +$0.09 (4.81%) After hours

$EDIT SEC Filings

Filed On Filing
13 Nov 2026 Form 4: O'Neill Gilmore Neil, Director

Sold 21,164 shares ($51.1K)

13 Nov 2026 Form 4: Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER

Sold 7,814 shares ($18.9K)

09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia

06 Nov 2026 Form 4: Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER

Received 16,533 shares as a grant or award

06 Nov 2026 Form 4: O'Neill Gilmore Neil, Director

Received 43,567 shares as a grant or award

27 Oct 2026 SCHEDULE 13G
08 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering

09 Sep 2026 Form 4: Ory Daniel Scott, EVP, Chief Medical Officer

Granted 950,000 Stock Option (right to buy)

09 Sep 2026 Form 3: Ory Daniel Scott, EVP, Chief Medical Officer

No securities owned

09 Sep 2026 S-8
08 Sep 2026 EFFECT
04 Sep 2026 Form 4: Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER

Sold 709 shares ($2.15K)

04 Sep 2026 Form 4: Parison Amy, SVP, Chief Financial Officer

Sold 453 shares ($1.38K)

04 Sep 2026 Form 4: O'Neill Gilmore Neil, Director

Sold 5,124 shares ($15.6K)

31 Aug 2026 S-3
31 Aug 2026 144
31 Aug 2026 144
14 Aug 2026 SCHEDULE 13G
07 Aug 2026 Form 4: Ellinor Patrick Thomas Ii, Director

Granted 103,400 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support